Venetoclax is a new anti-cancer option targeting non-specific gene mutations

Venetoclax, as an innovative targeted drug, is unique in that it does not directly target a specific gene mutation, but effectively promotes the natural apoptosis process of cancer cells by inhibiting the activity of BCL-2 protein. Although it does not directly act on genetic mutations, venetoclax has shown impressive efficacy in treating blood tumors that carry specific genetic mutations, such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).

In the field of CLL, mutations in genes such as TP53 and NOTCH1 are often closely related to tumor drug resistance and poor prognosis. However, studies have revealed that even in the face of these mutations that are difficult to overcome with traditional chemotherapy, venetoclax can still maintain a certain therapeutic activity, especially when used in combination with monoclonal antibodies (such as azilimab or rituximab), providing new treatment hope for patients with TP53 mutations.

For AML patients, gene mutations such as FLT3, IDH1/2 and NPM1 often affect treatment response and disease prognosis. Venetoclax has demonstrated significantly enhanced therapeutic effects when combined with other chemotherapy drugs, especially in patients with NPM1 mutations. Although these genetic mutations are not the direct targets of venetoclax, the synergistic effect of the drugs can change the biological behavior of tumor cells, thus improving the success rate of treatment.

The efficacy of venetoclax is mainly attributed to its inhibitory effect onBCL-2 protein. Since BCL-2 is overexpressed in a variety of blood tumors, inhibiting its activity has become an effective way to promote cancer cell apoptosis. Therefore, the therapeutic effect of venetoclax is closely related to the expression level of BCL-2 in tumor cells and its anti-apoptotic ability.

For patients scheduled to be treated with venetoclax, genetic testing remains key to developing a personalized treatment plan. By detecting specific gene mutations, doctors can more accurately select combination treatment strategies to maximize patient outcomes.